Skip to main content

Advertisement

SpringerLink
Log in

Inhibition of the renin–angiotensin system and chronic kidney disease

  • Nephrology - Review
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Chronic kidney disease (CKD), a major worldwide public-health problem which affects about 10% of the population, has an increased annual incidence rate of about 5–8%. This increased incidence is mainly due to type 2 diabetes and hypertension and the increasing incidence of elderly patients with CKD. Although the progression to end-stage renal failure (ESRF) is mainly based upon the underlying disease, comorbid conditions such as an initial low renal function, severe proteinuria, and high levels of blood pressure also play important roles in the development of ESRF. Since experimental and clinical evidence suggest that angiotensin II plays a central role in the progression of CKD, pharmacological inhibition of the renin–angiotensin–aldosteron system (RAAS) with angiotensin converting enzyme inhibitors or angiotensin II receptor antagonists has been suggested as first-line treatment for hypertension and prevention of ESRF in these patients. Aliskiren, a novel renin inhibitor is also a promising medical intervention. However, independently of the category of the drugs used, low target blood pressure levels seem to be equally or more important for the delay or prevention of CKD. In this review the results of studies with pharmacological inhibition of the RAAS in patients with diabetic and nondiabetic nephropathy is discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. USRD 2006 ADR/reference tables. Available at: http://www.usrds.org/reference_2006.htm 2008

  2. El-Nahas M (2005) The global challenge of chronic kidney disease. Kidney Int 68:2918–2929

    Article  PubMed  Google Scholar 

  3. Ishani A, Grandits GA, Grimm RH, Svendsen KH, Collins AJ, Prineas RJ, Neaton JD (2006) Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate, and hematocrit with 25-year incidence of end-stage renal disease in the multiple risk factor intervention trial. J Am Soc Nephrol 17:1444–1452

    Article  PubMed  CAS  Google Scholar 

  4. Perry HM Jr, Miller JP, Fornoff JR, Baty JD, Sambhi MP, Rutan G, Moskowitz DW, Carmody SE (1995) Early predictors of 15-year end-stage renal disease in hypertensive patients. Hypertension 25:587–594

    PubMed  Google Scholar 

  5. Ruggenenti P, Perna A, Gherardi G, Gaspari F, Benini R, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril efficacy in nephropathy. Lancet 352:1252–1256

    Article  PubMed  CAS  Google Scholar 

  6. Schaeffner ES, Kurth T, Bowman TS, Gelber RP, Gaziano JM (2007) Blood pressure measures and risk of chronic kidney disease in men. Nephrol Dial Transplant 4:1246–1251

    Article  Google Scholar 

  7. Coresh J, Astor BC, Greene T, Eknoyan G, Levey AS (2003) Prevalence of chronic kidney disease and decreased kidney function in the adult US population: Third National Health and Nutrition Examination Survey. Am J Kidney Dis 41:1–12

    Article  PubMed  Google Scholar 

  8. Willenheimer R, Dahlof B, Rydberg E et al (1999) AT1-receptor blockers in hypertension and heart failure: clinical experience and future directions. Eur Heart J 20:997–1008

    Article  PubMed  CAS  Google Scholar 

  9. Karalliedde J, Viberti G (2006) Evidence for renoprotection by blockade of the renin–angiotensin–aldosterone system in hypertension and diabetes. J Hum Hypertens 20:239–253

    Article  PubMed  CAS  Google Scholar 

  10. Zanchetti A, Ruilope LM (2002) Antihypertensive treatment in patients with type–2 diabetes mellitus: what guidance from recent controlled randomized trials? J Hypertens 20:2099–2110

    Article  PubMed  CAS  Google Scholar 

  11. Mancia G, De BG, Dominiczak A, Cifkova R et al (2007) 2007 Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187

    Article  PubMed  CAS  Google Scholar 

  12. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia) (1997) Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 349:1857–1863

    Google Scholar 

  13. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, RENAAL Study Investigators (2001) Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 345:861–869

    Article  PubMed  CAS  Google Scholar 

  14. Kasiske BL, Kalil RS, Ma JZ, Liao M, Keane WF (1993) Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis. Ann Intern Med 118:129–138

    PubMed  CAS  Google Scholar 

  15. Ruggenenti P, Perna A, Mosconi L, Pisoni R, Remuzzi G (1998) Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. “Gruppo Italiano di Studi Epidemiologici in Nefrologia” (GISEN). Kidney Int 53:1209–1216

    Article  PubMed  CAS  Google Scholar 

  16. Ruggenenti P, Fassi A, Ilieva AP et al (2004) Preventing microalbuminuria in type 2 diabetes. N Engl J Med 351:1941–1951

    Article  PubMed  CAS  Google Scholar 

  17. Suissa S, Hutchinson T, Brophy JM, Kezouh A (2006) ACE-inhibitor use and the long-term risk of renal failure in diabetes. Kidney Int 69:913–919

    Article  PubMed  CAS  Google Scholar 

  18. Covic A, Gusbeth-Tatomir P, Goldsmith DJ (2007) Current dilemmas in inhibiting the renin–angiotensin system: do not forget real life. Int Urol Nephrol 39:571–576

    Article  PubMed  Google Scholar 

  19. Rossing P, Parving HH, de Zeeuw D (2006) Renoprotection by blocking the RAAS in diabetic nephropathy–fact or fiction? Nephrol Dial Transplant 21:2354–2357

    Article  PubMed  Google Scholar 

  20. Casas JP, Chua W, Loukogeorgakis S, Vallance P, Smeeth L, Hingorani AD, MacAllister RJ (2005) Effect of inhibitors of the renin–angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet 366:2026–2033

    Article  PubMed  CAS  Google Scholar 

  21. Luft FC, Weinberger MH (2007) Antihypertensive therapy with aliskiren. Kidney Int. doi:10.1038/sjki5002732

  22. Luther RR, Glassman HN, Boger RS (1991) Renin inhibitors in hypertension. Clin Nephrol 36:181–186

    PubMed  CAS  Google Scholar 

  23. Muller DN, Luft FC (2006) Direct renin inhibition with aliskiren in hypertension and target organ damage. Clin J Am Soc Nephrol 1:221–228

    Article  PubMed  CAS  Google Scholar 

  24. Oh BH (2007) Aliskiren, the first in a new class of direct renin inhibitors for hypertension: present and future perspectives. Expert Opin Pharmacother 8:2839–2849

    Article  PubMed  CAS  Google Scholar 

  25. Pilz B, Shagdarsuren E, Wellner M, Fiebeler A, Dechend R, Gratze P, Meiners S, Feldman DL, Webb RL, Garrelds IM, Jan Danser AH, Luft FC, Müller DN (2005) Aliskiren, a human renin inhibitor, ameliorates cardiac and renal damage in double-transgenic rats. Hypertension 46:569–576

    Article  PubMed  CAS  Google Scholar 

  26. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD (1993) The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 329:1456–1462

    Article  PubMed  CAS  Google Scholar 

  27. Tarnow L, Rossing P, Jensen C, Hansen BV, Parving HH (2000) Long-term renoprotective effect of nisoldipine and lisinopril in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 23:1725–1730

    Article  PubMed  CAS  Google Scholar 

  28. Ruggenenti P, Perna A, Gherardi G, Garini G, Zoccali C, Salvadori M, Scolari F, Schena FP, Remuzzi G (1999) Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 354:359–364

    Article  PubMed  CAS  Google Scholar 

  29. Maschio G, Alberti D, Janin G, Locatelli F, Mann JF, Motolese M, Ponticelli C, Ritz E, Zucchelli P (1996) Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med 334:939–945

    Article  PubMed  CAS  Google Scholar 

  30. Parving HH, Hovind P, Rossing K (2001) Evolving strategies for renoprotection: diabetic nephropathy. Curr Opin Nephrol Hypertens 10:515–522

    Article  PubMed  CAS  Google Scholar 

  31. Mogensen CE (1984) Microalbuminuria predicts clinical proteinuria and early mortality in maturity-onset diabetes. N Engl J Med 310:356–360

    PubMed  CAS  Google Scholar 

  32. Nelson RG, Knowler WC, Pettitt DJ, Saad MF, Charles MA, Bennett PH (1991) Assessment of risk of overt nephropathy in diabetic patients from albumin excretion in untimed urine specimens. Arch Intern Med 151:1761–1765

    Article  PubMed  CAS  Google Scholar 

  33. Bigazzi R, Bianchi S, Baldari D, Campese VM (1998) Microalbuminuria predicts cardiovascular events and renal insufficiency in patients with essential hypertension. J Hypertens 16:1325–1333

    Article  PubMed  CAS  Google Scholar 

  34. de Leeuw PW, Ruilope LM, Palmer CR, Brown MJ, Castaigne A, Mancia G, Rosenthal T, Wagener G (2004) Clinical significance of renal function in hypertensive patients at high risk: results from the INSIGHT trial. Arch Intern Med 164:2459–2464

    Article  PubMed  Google Scholar 

  35. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S, HOPE Study Investigators (2001) Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286:421–426

    Article  PubMed  CAS  Google Scholar 

  36. Jager A, Kostense PJ, Ruhé HG, Heine RJ, Nijpels G, Dekker JM, Bouter LM, Stehouwer CD (1999) Microalbuminuria and peripheral arterial disease are independent predictors of cardiovascular and all-cause mortality, especially among hypertensive subjects: five-year follow-up of the Hoorn Study. Arterioscler Thromb Vasc Biol 19:617–624

    PubMed  CAS  Google Scholar 

  37. Jensen JS, Feldt-Rasmussen B, Strandgaard S, Schroll M, Borch-Johnsen K (2000) Arterial hypertension, microalbuminuria, and risk of ischemic heart disease. Hypertension 35:898–903

    PubMed  CAS  Google Scholar 

  38. Sarnak MJ, Levey AS, Schoolwerth AC et al (2003) Kidney disease as a risk factor for development of cardiovascular disease: a statement from the American Heart Association councils on kidney in cardiovascular disease high blood pressure research, clinical cardiology and epidemiology and prevention. Circulation 108:2154–2169

    Article  PubMed  Google Scholar 

  39. Wachtell K, Ibsen H, Olsen MH et al (2003) Albuminuria and cardiovascular risk in hypertensive patients with left ventricular hypertrophy: the LIFE study. Ann Intern Med 139:901–906

    PubMed  Google Scholar 

  40. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G (2000) Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcomes prevention evaluation study investigators. N Engl J Med 342:145–153

    Article  PubMed  CAS  Google Scholar 

  41. The EUCLID Study Group (1997) Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet 349:1787–1792

    Google Scholar 

  42. Ravid M, Brosh D, Levi Z, Bar-Dayan Y, Ravid D, Rachmani R (1998) Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus. A randomized, controlled trial. Ann Intern Med 128:982–988

    PubMed  CAS  Google Scholar 

  43. Hou FF, Zhang X, Zhang GH, Xie D, Chen PY, Zhang WR, Jiang JP, Liang M, Wang GB, Liu ZR, Geng RW (2006) Efficacy and safety of benazepril for advanced chronic renal insufficiency. N Engl J Med 354:131–140

    Article  PubMed  CAS  Google Scholar 

  44. Berl T, Hunsicker LG, Lewis JB et al (2003) Cardiovascular outcomes in the Irbesartan diabetic nephropathy trial of patients with type 2 diabetes and overt nephropathy. Ann Intern Med 138:542–549

    PubMed  CAS  Google Scholar 

  45. Parving HH, Lehnert H, Bröchner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group (2001) The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 345:870–878

    Article  PubMed  CAS  Google Scholar 

  46. Viberti G, Wheeldon NM (2002) Microalbuminuria reduction with valsartan in patients with type 2 diabetes mellitus: a blood pressure-independent effect. Circulation 106:672–678

    Article  PubMed  CAS  Google Scholar 

  47. Kunz R, Friedrich C, Wolbers M, Mann JF (2008) Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 148:30–48

    PubMed  Google Scholar 

  48. Andersen S, Rossing P, Juhl TR, Deinum J, Parving HH (2002) Optimal dose of losartan for renoprotection in diabetic nephropathy. Nephrol Dial Transplant 17:1413–1418

    Article  PubMed  CAS  Google Scholar 

  49. Hollenberg NK, Parving HH, Viberti G, Remuzzi G, Ritter S, Zelenkofske S, Kandra A, Daley WL, Rocha R (2007) Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. J Hypertens 25:1921–1926

    Article  PubMed  CAS  Google Scholar 

  50. Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH (2005) Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 68:1190–1198

    Article  PubMed  CAS  Google Scholar 

  51. Schmieder RE, Klingbeil AU, Fleischmann EH, Veelken R, Delles C (2005) Additional antiproteinuric effect of ultrahigh dose candesartan: a double-blind, randomized, prospective study. J Am Soc Nephrol 16:3038–3045

    Article  PubMed  CAS  Google Scholar 

  52. Laverman GD, Navis G, Henning RH, de Jong PE, de Zeeuw D (2002) Dual renin–angiotensin system blockade at optimal doses for proteinuria. Kidney Int 62:1020–1025

    Article  PubMed  CAS  Google Scholar 

  53. Matchar DB, McCrory DC, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN (2008) Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med 148:16–29

    PubMed  Google Scholar 

  54. Barnett AH, Bain SC, Bouter P, Karlberg B, Madsbad S, Jervell J, Mustonen J; Diabetics Exposed to Telmisartan and Enalapril Study Group (2004) Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy. N Engl J Med 351:1952–1961

    Article  PubMed  CAS  Google Scholar 

  55. Bakris GL, Ruilope L, Locatelli F, Ptaszynska A, Pieske B, de Champlain J, Weber MA, Raz I (2007) Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial. Kidney Int 72:879–885

    Article  PubMed  CAS  Google Scholar 

  56. Kincaid-Smith P, Fairley K, Packham D (2002) Randomized controlled crossover study of the effect on proteinuria and blood pressure of adding an angiotensin II receptor antagonist to an angiotensin converting enzyme inhibitor in normotensive patients with chronic renal disease and proteinuria. Nephrol Dial Transplant 17:597–601

    Article  PubMed  CAS  Google Scholar 

  57. Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T (2003) Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 361:117–124

    Article  PubMed  CAS  Google Scholar 

  58. Kincaid-Smith P, Fairley KF, Packham D (2004) Dual blockade of the renin–angiotensin system compared with a 50% increase in the dose of angiotensin-converting enzyme inhibitor: effects on proteinuria and blood pressure. Nephrol Dial Transplant 19:2272–2274

    Article  PubMed  CAS  Google Scholar 

  59. Kidney Disease Outcome Quality Initiative (2004) K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis 43(5 Suppl 1):S65–S230

    Google Scholar 

  60. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK, AVOID Study Investigators (2008) Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med 358(23):2433–2446

    Article  PubMed  CAS  Google Scholar 

  61. Toto R, Palmer BF (2007) Rationale for combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor treatment and end-organ protection in patients with chronic kidney disease. Am J Nephrol 28:372–380

    Article  PubMed  CAS  Google Scholar 

  62. Teo K, Yusuf S, Sleight P et al (2004) Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. Am Heart J 148:52–61

    Article  PubMed  CAS  Google Scholar 

  63. Azizi M, Webb R, Nussberger J, Hollenberg NK (2006) Renin inhibition with aliskiren: where are we now, and where are we going? J Hypertens 24:243–256

    Article  PubMed  CAS  Google Scholar 

  64. Brewster UC, Setaro JF, Perazella MA (2003) The renin–angiotensin–aldosterone system: cardiorenal effects and implications for renal and cardiovascular disease states. Am J Med Sci 326:15–24

    Article  PubMed  Google Scholar 

  65. Stanton A (2003) Therapeutic potential of renin inhibitors in the management of cardiovascular disorders. Am J Cardiovasc Drugs 3:389–394

    Article  PubMed  CAS  Google Scholar 

  66. Stanton A, Jensen C, Nussberger J, O’Brien E (2003) Blood pressure lowering in essential hypertension with an oral renin inhibitor, aliskiren. Hypertension 42:1137–1143

    Article  PubMed  CAS  Google Scholar 

  67. Stanton A (2003) Potential of renin inhibition in cardiovascular disease. J Renin Angiotensin Aldosterone Syst 4:6–10

    Article  PubMed  CAS  Google Scholar 

  68. Wood JM, Maibaum J, Rahuel J et al (2003) Structure-based design of aliskiren, a novel orally effective renin inhibitor. Biochem Biophys Res Commun 308:698–705

    Article  PubMed  CAS  Google Scholar 

  69. Drummond W, Munger MA, Rafique EM (2007) Antihypertensive efficacy of the oral direct Renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy. J Clin Hypertens (Greenwich) 9:742–750

    Article  CAS  Google Scholar 

  70. O’Brien E, Barton J, Nussberger J, Mulcahy D, Jensen C, Dicker P, Stanton A (2007) Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker. Hypertension 49:276–284

    Article  PubMed  CAS  Google Scholar 

  71. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A (2007) Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial. Lancet 370:221–229

    Article  PubMed  CAS  Google Scholar 

  72. Berne C, Pollare T, Lithell H (1991) Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care 14(Suppl 4):39–47

    PubMed  Google Scholar 

  73. Kostis JB, Shelton B, Gosselin G, Goulet C, Hood WB Jr, Kohn RM, Kubo SH, Schron E, Weiss MB, Willis PW 3rd, Young JB, Probstfield J (1996) Adverse effects of enalapril in the Studies of Left Ventricular Dysfunction (SOLVD). SOLVD Investigators. Am Heart J 131:350–355

    Article  PubMed  CAS  Google Scholar 

  74. Baraldi A, Ballestri M, Rapanà R, Lucchi L, Borella P, Leonelli M, Furci L, Lusvarghi E (1998) Acute renal failure of medical type in an elderly population. Nephrol Dial Transplant 13(Suppl 7):25–29

    Article  PubMed  Google Scholar 

  75. Loboz KK, Shenfield GM (2005) Drug combinations and impaired renal function—the ‘triple whammy’. Br J Clin Pharmacol 59:239–243

    Article  PubMed  CAS  Google Scholar 

  76. Gupta RK, Kapoor A, Tewari S, Sinha N, Sharma RK (1999) Captopril for prevention of contrast-induced nephropathy in diabetic patients: a randomised study. Indian Heart J 51:521–526

    PubMed  CAS  Google Scholar 

  77. Bakris GL, Weir MR (2000) Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med 160:685–693

    Article  PubMed  CAS  Google Scholar 

  78. Cirit M, Toprak O, Yesil M, Bayata S, Postaci N, Pupim L, Esi E (2006) Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 104:c20–c27

    Article  PubMed  CAS  Google Scholar 

  79. Toprak O, Cirit M, Bayata S, Yesil M, Aslan SL (2003) The effect of pre-procedural captopril on contrast-induced nephropathy in patients who underwent coronary angiography. Anadolu Kardiyol Derg 3:98–103

    PubMed  Google Scholar 

  80. Mahajan S, Tiwari S, Bhowmik D, Agarwal SK, Tiwari SC, Dash SC (2006) Factors affecting the outcome of acute renal failure among the elderly population in India: a hospital based study. Int Urol Nephrol 38:391–396

    Article  PubMed  Google Scholar 

  81. Rosenstock JL, Bruno R, Kim JK, Lubarsky L, Schaller R, Panagopoulos G, DeVita MV, Michelis MF (2008) The effect of withdrawal of ACE inhibitors or angiotensin receptor blockers prior to coronary angiography on the incidence of contrast-induced nephropathy. Int Urol Nephrol. doi:10.1007/s11255-008-9368-1

    PubMed  Google Scholar 

  82. Gami AS, Garovic VD (2004) Contrast nephropathy after coronary angiography. Mayo Clin Proc 79:211–219

    Article  PubMed  Google Scholar 

  83. Maeder M, Klein M, Fehr T, Rickli H (2004) Contrast nephropathy: review focusing on prevention. J Am Coll Cardiol 44:1763–1771

    Article  PubMed  Google Scholar 

  84. Chobanian AV, Bakris GL, Black HR et al (2003) The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA 289:2560–2572

    Article  PubMed  CAS  Google Scholar 

  85. Bakris GL, Williams M, Dworkin L, Elliott WJ, Epstein M, Toto R, Tuttle K, Douglas J, Hsueh W, Sowers J (2000) Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36:646–661

    PubMed  CAS  Google Scholar 

  86. Koshy S, Bakris GL (2000) Therapeutic approaches to achieve desired blood pressure goals: focus on calcium channel blockers. Cardiovasc Drugs Ther 14:295–301

    Article  PubMed  CAS  Google Scholar 

  87. Wright JT Jr, Bakris G, Greene T et al (2002) Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA 288:2421–2431

    Article  PubMed  CAS  Google Scholar 

  88. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, Levey AS, AIPRD Study Group (2003) Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 139:244–252

    PubMed  CAS  Google Scholar 

  89. Schrier RW, Estacio RO, Mehler PS, Hiatt WR (2007) Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. Nat Clin Pract Nephrol 3:428–438

    Article  PubMed  Google Scholar 

  90. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G (1994) The effects of dietary protein restriction and blood-pressure control on the progression of chronic renal disease. Modification of Diet in Renal Disease Study Group. N Engl J Med 330:877–884

    Article  PubMed  CAS  Google Scholar 

  91. Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, Levey AS (2005) The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med 142:342–351

    PubMed  Google Scholar 

  92. Parving HH, Andersen AR, Smidt UM, Hommel E, Mathiesen ER, Svendsen PA (1987) Effect of antihypertensive treatment on kidney function in diabetic nephropathy. Br Med J (Clin Res Ed) 294:1443–1447

    CAS  Google Scholar 

  93. Brenner BM (2003) Retarding the progression of renal disease. Kidney Int 64:370–378

    Article  PubMed  Google Scholar 

  94. Covic A, Gusbeth-Tatomir P, Goldsmith DJ (2007) Current dilemmas in inhibiting the renin-angiotensin system: do not forget real life. Int Urol Nephrol 39(2):571–576

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Medical School, University of Ioannina, 451 10, Ioannina, Greece

    Kostas C. Siamopoulos & Rigas G. Kalaitzidis

Authors
  1. Kostas C. Siamopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rigas G. Kalaitzidis
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kostas C. Siamopoulos.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Siamopoulos, K.C., Kalaitzidis, R.G. Inhibition of the renin–angiotensin system and chronic kidney disease. Int Urol Nephrol 40, 1015–1025 (2008). https://doi.org/10.1007/s11255-008-9424-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-008-9424-x

Keywords

Search

Navigation